Exploring the Dual Impact of GLP-1 Receptor Agonists on Addiction and Side Effects

The increasing use of glucagon-like peptide-1 receptor agonists (GLP-1RAs) continues to broaden our understanding of these medications. Initially developed to manage type 2 diabetes and short bowel syndrome, GLP-1RAs gained popularity for aiding in obesity management, with well-known brands like Ozempic and Wegovy now mainstream. Recent data indicates that approximately 12% of U.S. adults utilize GLP-1RAs for weight loss, diabetes, or other chronic conditions, and this figure is predicted to rise to 40% with the recent approval of Wegovy in pill form.

As these medications surge in acceptance and use, researchers are exploring their effects beyond obesity and diabetes. Notably, GLP-1RAs have demonstrated potential in reducing consumption of alcohol and in addressing various addictions, such as those related to gambling and sex.

In a recent publication in the Journal of the Endocrine Society (JES), authors discuss the role of GLP-1 in treating substance use disorders. The paper indicates a significant overlap between the mechanisms of obesity and addiction, with research suggesting that neurocircuitry implicated in addiction may also contribute to overeating and obesity.

According to Lorenzo Leggio, MD, PhD, who is the clinical director of the National Institute on Drug Abuse, current research shows that some neuroimaging features found in people suffering from obesity echo those seen in patients with addiction. He notes that specific pathways linked to addiction also play a role in controlling appetite and body weight. Leggio emphasizes that the gut-brain relationship might be pivotal for addressing alcohol use disorder (AUD) and other substance use disorders.

His lab has embarked on investigating how hormonal signals affect these disorders, focusing particularly on insulin, ghrelin, and GLP-1.

Despite the encouraging findings, opioid treatment for alcohol and substance use disorders primarily encompasses behavioral therapy and a limited number of FDA-sanctioned medications. The stigma surrounding these disorders often limits patients’ willingness to seek help.

Leggio stresses the necessity of integrating addiction medicine into medical education to ensure clinicians can identify and manage these conditions effectively. Education is vital for reducing the stigma associated with alcohol and substance use disorders, which is essential to maximizing the impact of available and prospective treatments.

Evidence suggests GLP-1RAs may aid in reducing alcohol intake; both preclinical studies involving rodents and anecdotal reports from humans imply that these medications might decrease alcohol consumption. Although patients have relayed experiences of reduced drinking after beginning treatment with GLP-1RAs, these accounts are anecdotal and not formal clinical evidence.

Leggio clarifies that while early findings are promising for the therapeutic potential of GLP-1RAs in substance use disorders, there is an urgent need for comprehensive randomized controlled trials to conclusively validate these benefits and identify the best candidates for treatment.

Alongside these potential benefits, clinicians must remain vigilant about the rare but serious side effects associated with GLP-1RAs. A noteworthy article published in February 2025 elucidates a case of a patient who developed euglycemic ketoacidosis after being prescribed tirzepatide—a medication that combines GLP-1 and glucose-dependent insulinotropic peptide receptor agonists—alongside an SGLT2 inhibitor. It is suggested that this combination could lead to a significant interaction, resulting in effective blood sugar control but also inducing a state that demands intensive medical supervision.

This patient required intensive care for recovery, highlighting the need for awareness of potential severe complications when administering newly approved medications like tirzepatide. Eli J. Louwagie, MD, PhD, emphasizes that understanding the full spectrum of side effects remains critical as GLP-1RAs become more common in clinical practice.

Louwagie underlines that further investigation is necessary to explore the risk of adverse effects in patients on such combinations. He adds that the recent shift in medication prescribing practices could yield substantial patient data, enabling deeper insight into potential risks.

In a related commentary by Christine Rode Schwarz, PhD, and co-authors, the importance of individualizing treatment is reaffirmed. They note that while most patients taking GLP-1 therapies experience significant benefits with minimal adverse reactions, understanding which patient characteristics may predispose individuals to complications remains an essential focus for ongoing research.

Schwarz advocates for mindful and well-substantiated administration of GLP-1 therapies, highlighting their substantial advantages in managing glycemia, weight, and, in particular scenarios, cardiovascular risks. Adverse effects often represent the interaction of pharmacology within the unique context of each patient. Thus, thoughtful prescribing is vital for achieving safe and effective outcomes.

Both Louwagie and Schwarz acknowledge that this evolving field necessitates ongoing education and careful consideration of each patient’s circumstances to optimize treatment efficacy. The knowledge accrued regarding GLP-1RAs will play a pivotal role in shaping future treatment protocols for obesity, addictions, and metabolic disorders.

The article illustrates that while GLP-1 receptor agonists show remarkable promise in managing various conditions, an understanding of their risks is paramount for clinicians. As their application broadens, so too must our grasp of their full impact on different patient populations.